GANX News and Press, Gain Therapeutics Inc. From 09/25/23

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Exec...

BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matth...

2023-09-18 17:06:48 ET Gainers: Gain Therapeutics ( NASDAQ: GANX ) +7% . QuidelOrtho  ( QDEL ) +5% . ARS Pharmaceuticals ( SPRY ) +5% . ProFrac Holding  ( ACDC ) +5% . Clean Energy Fuels  ( CLNE ) +4% . L...

First drug candidate identified with Gain’s proprietary computational drug discovery platform SEE-Tx ® to enter clinical development phase BETHESDA, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company&#...

--News Direct-- Bethesda, MD, August 29, 2023 ( PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. ( Nasdaq: GANX ), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's ...

(NewsDirect) Bethesda, MD, August 29, 2023 ( PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. ( Nasdaq: GANX ), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's dis...

Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function Data presented at the International Congress of Parkinson's Disease a...

2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...

2023-08-10 10:31:02 ET Gain Therapeutics press release ( NASDAQ: GANX ): Q2 GAAP EPS of -$0.62. Cash, cash equivalents and marketable securities were $16.2 million as of June 30, 2023, For further details see: Gain Therapeutics GAAP EPS of -$0.62

HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson’s Disease and Movement Disorders ® in Copenhagen, Denmark BETHESDA...